VJOncology is committed to improving our service to you

ESMO 2019 | Prof. Siefker-Radtke on the EV-103 trial in bladder cancer

VJOncology is committed to improving our service to you

Arlene Siefker-Radtke

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses her thoughts on the latest news in bladder cancer at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain – the EV-103 trial of enfortumab vedotin combined with pembrolizumab (NCT03288545).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter